Why the study?
Does oral fenoldopam act as a renal vasodilator and increase urine volume and clearance via dopamine receptor stimulation in humans?
Does oral fenoldopam act as a renal vasodilator and increase urine volume and clearance via dopamine receptor stimulation in humans?
Oral fenoldopam is an active renal vasodilator in humans that increases urine volume and sodium excretion through the stimulation of renal dopamine receptors.
Answers are grounded in this paper and cite their sources.
Supports dopamine-mediated renal effects of oral fenoldopam; hypothesis-generating and should not yet change practice.
Fenoldopam, a dopamine agonist, was evaluated in renal clearance studies during water diuresis after oral doses of 25, 50, and 100 mg. After the 100-mg dose there was an increase in urine flow rate, paraaminohippurate clearance, free water clearance, and an increase in the fractional excretion of sodium, calcium, and uric acid. These effects were evident within the first hour, peaked during the second hour, and lasted about 3 hr. Doses of 50 and 25 mg induced smaller increases. There was no significant change in inulin clearance at any dose. To elucidate the mechanism of action, the studies were repeated after treatment with a dopamine-receptor antagonist (metoclopramide). Metoclopramide greatly diminished the renal effects of fenoldopam. These findings indicate that fenoldopam is an active renal vasodilator in man and increases urine volume, free water clearance, and fractional excretion of sodium by stimulation of renal dopamine receptors.
No takes yet. Share an insight, caveat, or question.
Stote et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: